|Bid||2.32 x 0|
|Ask||2.35 x 0|
|Day's Range||2.21 - 2.35|
|52 Week Range||0.42 - 3.23|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience (CSE:LXX) (LXRP), a client of NNW focused on developing and out-licensing its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids and nicotine. Lexaria recently announced the results of its second in vivo study of 2018 evaluating the use of DehydraTECH as a nicotine delivery system. Speed of absorption is one of the most important issues for non-inhalation forms of nicotine delivery, given the rapidity with which smoking gets the drug into the body, so this is a strong sign for the potential of DehydraTECH as a smoking alternative.
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of a CEO video interview and article discussing Lexaria Bioscience Corp. (CSE:LXX) (CN) (CNSX:LXX) (LXRP). In recent in-vivo animal studies, the company demonstrated that its delivery technology achieved nearly double the delivery than non tech-enhanced edible forms of nicotine, as well as significantly improve nicotine absorption across all subsequent time points — making it a compelling nicotine replacement option. While the negative side-effects of smoking have reduced cigarette volumes, many existing smokers don’t have a viable alternative that delivers nicotine quickly enough into the bloodstream.
This study represents Lexaria's second in vivo nicotine study, building on the previous nicotine breakthrough study announced April 17, 2018. CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has successfully delivered nicotine in an edible form into blood plasma just minutes after dosing in an animal in vivo study. Speed of onset is a key attribute for oral drug administration, and it is of particular importance for the consideration of non-inhalation nicotine delivery formats.
The company has spent the past several years focused on improving the bioavailability of cannabinoids, including CBD. Its DehydraTECH™ drug delivery platform has demonstrated significant improvements in bioavailability over conventional delivery methods — and its latest human clinical study confirmed these findings.
KELOWNA, BC / ACCESSWIRE / August 1, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to report ...
"Hill Street") jointly announced that they have signed a Definitive Agreement to license Lexaria's DehydraTECHTM, on a semi-exclusive basis, for a term of five (5) years, to produce a line of cannabis-infused alcohol-free beverages for Canadian distribution, following regulatory approval. The Definitive Agreement is the conclusion of the process begun following the announcement of the non-binding letter of intent in April 2018. Terms of the Definitive Agreement were not disclosed.
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Lexaria Biosciences Inc. (CSE:LXX) (LXX.CN) (CNSX:LXX) (LXRP), which originally developed its DehydraTECH™ platform to increase the bioavailability of cannabinoids. The company has since broadened its focus well-beyond the cannabis industry. A recent discovery suggests that the proprietary platform may be effective in enabling researchers to deliver APIs past the blood brain barrier.
KELOWNA, BC / ACCESSWIRE / July 3, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special ...
TORONTO , June 29, 2018 /CNW/ - Horizons ETFs Management (Canada ) Inc. (" Horizons ETFs ") has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences ...
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / June 29, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has filed an important new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more. In recent laboratory testing, Lexaria's breakthrough discovery evidenced greatly enhanced drug delivery to brain tissue. Nicotine in-vivo (animal) studies showed that up to 560% more nicotine was delivered to brain tissue utilizing DehydraTECHTM than concentration-matched controls lacking DehydraTECHTM enhancements.
The company addresses the shortcomings of precise dosing across a wide range of delivery systems with its DehydraTECH™ drug delivery platform. By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the bitter and earthy taste of cannabis oil and ensures quick and effective transportation into the bloodstream without degradation in the stomach or liver. Lexaria’s technology now has over 40 patents pending and four patents already granted in the US.
The company is paving the road in terms of cannabinoid delivery research and development. CFN Media spoke with Lexaria CEO Chris Bunka at the recent MJBizNEXT Conference in New Orleans to learn more about the firm’s innovation and their plans to dramatically change the way people think about cannabis.
KELOWNA, BC / ACCESSWIRE / May 31, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that, subject to ongoing legal and tax analysis, it intends to create two wholly-owned subsidiaries that will respectively hold the intellectual property (''IP'') related to, in the case of the first subsidiary, the improved processing and combustion-free delivery of nicotine and nicotine analogs and, in the case of the second subsidiary, delivery of non-steroidal anti-inflammatory drugs (''NSAIDs''), phosphodiesterase (''PDE5'') inhibitors and other active pharmaceutical ingredients. This proposed structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each.
KELOWNA, B.C. / ACCESSWIRE / May 28, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces warrant transactions. Lexaria announces it has received US$63,000 from the exercise of warrants previously granted. The Company has received for exercise a total of 450,000 warrants with an exercise price of US$0.14, previously granted.
KELOWNA, BC / ACCESSWIRE / May 23, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received notifications that it has received two new US patents granted and additionally expects three new Australian patents granted on or before August 17th. Once granted, Lexaria will have 4 granted patents in the US and 4 granted patents in Australia. All eight of these patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof", and significantly strengthen Lexaria's intellectual property ("IP") claims in the US and Australia.
KELOWNA, BC / ACCESSWIRE / April 25, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered ...
KELOWNA, BC / ACCESSWIRE / April 23, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce that it has commenced ...
New York, New York--(Newsfile Corp. - April 20, 2018) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for business, today announces the audio version of the Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recent press release titled "Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology."To hear the Lexaria AudioPressRelease (APR) version, visit: http://nnw.fm/cJ6e5To read the original press release, visit: http://nnw.fm/u4DbMAbout Lexaria Bioscience Corp.Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that ...